

## Finance and Performance Assurance Committee Key Issues Report

<b>Report Date:</b> 2 <sup>nd</sup> February 2021		<b>Report of:</b> Finance and Performance Assurance Committee
<b>Date of last meeting:</b> 2 <sup>nd</sup> February 2021		<b>Membership Numbers:</b> The meeting was quorate.
1	<b>Agenda</b>	<p>The Committee considered an agenda which included the following:</p> <ul style="list-style-type: none"> <li>• Integrated Performance Report (Operational, Finance and Workforce sections)</li> <li>• COVID-19 Update</li> <li>• Finance Report Month 9</li> <li>• Revised Capital Programme 2020/21</li> <li>• EU Exit Update</li> <li>• Progress on delivery of key objectives for 2020/21</li> <li>• 2021/22 Draft Integrated Plan Update</li> <li>• Summary Business Case – Digital Pathology</li> <li>• Memorandum of Understanding for the allocation of capital funding for Laboratory Information Management System Enhancement Programme</li> <li>• Memorandum of Understanding for the Allocation of funding to support International Nurse Recruitment Programme Strand B</li> <li>• Memorandum of Understanding for the allocation of funding to support Healthcare Support Worker Recruitment</li> <li>• ICNET Business Case</li> <li>• Contracts Award Summary</li> </ul>
2a	<b>Alert</b>	<p>The Committee wish to alert members of the Board that:</p> <ul style="list-style-type: none"> <li>• The increase in COVID-19 cases has impacted on every part of the organisation, ie staff, services and space and should not be underestimated.</li> <li>• A plan is required for the management of elective activity, validation of the waiting list and a review of priorities for when the Trust comes out of the pandemic.</li> </ul>
2b	<b>Assurance</b>	<p>The Committee wish to assure members of the Board that:</p> <ul style="list-style-type: none"> <li>• Cancer performance continues to be a key priority, and in comparison to other organisations, the Trust is performing reasonably despite impact on tertiary cancer centres.</li> <li>• There has been an improvement in DMO1 Diagnostic performance, with elements of the service working across 7 days and significantly supported by additional mobile MRI and CT scanners.</li> <li>• There were no issues to date arising for the Trust following the UK's exit from the EU on 31<sup>st</sup> December 2021.</li> </ul>

2c	<b>Advise</b>	<p>The Committee wish to advise members of the Board that:</p> <ul style="list-style-type: none"> <li>• The Trust reported a year to date deficit of £2.093 million, £0.505 million favourable to the revised plan. The Trust is forecasting to achieve its control total of a deficit of £7.724 million in 2020/21.</li> <li>• A review of the agreed capital schemes to establish their deliverability before 31<sup>st</sup> March 2021 had taken place. As a result a revised Capital Programme was presented to and <b>recommended by the Committee to the Board of Directors for approval.</b></li> <li>• Clarification on developing the process by which the committee gains validation and assurance from the updates it receives on the delivery of the key objectives for 2020/21 was sought.</li> <li>• An update on the development of the Integrated Plan for 2021/22 was received. Baseline planning assumptions are still to be confirmed and refined once national planning guidance is published.</li> <li>• Support was given to the Business Cases for Digital Pathology and ICNET which would provide much needed investment in the areas of Pathology and Infection Prevention and Control and <b>recommended approval of these by the Board of Directors.</b></li> <li>• The Committee confirmed their support of the signing of the Memorandum of Understandings for: <ul style="list-style-type: none"> <li>• Laboratory Information Management System Enhancement Programme. This will be added to the Capital Programme for approval by the Board of Directors.</li> <li>• International Nurse Recruitment Programme Strand B</li> <li>• Healthcare Support Worker Recruitment</li> </ul> <b>and recommended approval of this by the Board of Directors.</b> </li> <li>• Confirmation of the funding allocation to replace the aged breast screening mammography equipment at the Trust had been received. This will be added to the Capital Programme for approval by the Board of Directors. A Memorandum of Understanding would be received in due course for signature.</li> </ul>		
2d	<b>Review of Risks</b>	<b>The BAF was not considered on this occasion. However, it was recommended that the BAF risk relating to EU Exit (BAF10) should now be closed.</b>		
3	<b>Actions to be considered by the Board</b>	<ul style="list-style-type: none"> <li>• Committee Summary to be noted.</li> <li>• <b>Consideration and approval of:</b> <ul style="list-style-type: none"> <li>○ Revised Capital Programme 2020/21, updated to reflect LIMS and digital mammography equipment.</li> <li>○ Summary Business Case – Digital Pathology</li> <li>○ the signing of the Memorandum of Understandings for: <ul style="list-style-type: none"> <li>▪ Laboratory Information Management System Enhancement Programme</li> <li>▪ International Nurse Recruitment Programme Strand B</li> <li>▪ Healthcare Support Worker Recruitment</li> </ul> </li> <li>○ ICNET Business Case</li> <li>○ MOU for Digital Mammography Breast Screening Replacement Programme will be issued in due course for signature</li> </ul> </li> </ul>		
4	<b>Report compiled by</b>	<i>Trevor Purt Acting Chair</i>	<b>Minutes available from</b>	<i>Amanda Young Committee Support</i>